Talawar Therapeutics
Definitive (DA signed)Pre-revenueHealthcare · Biotechnology / bispecific antibodies for immunology & inflammation (I&I) · New York, United States
- What it is
- Khanda-model asset developer: unites two validated orthogonal I&I pathways in single bispecific molecules and funds them to clinical proof-of-concept; no products, no revenue - funded entirely by the SPAC trust ($60M pre-redemption) and the $225M PIPE (total ~$285M gross assuming no redemptions).
- What it’s doing now
- Merging with JATT II Acquisition (JATT) — definitive (da signed), announced Jun 29, 2026.
- What you should know
- It reports no meaningful revenue yet — this deal is priced on a story, not on financials. The real share count puts the effective valuation 252% above the announced $120M. The deal carries a $125M minimum-cash condition — heavy redemptions can break it.
The business, per its filings
SEC primaryTalawar Tx Inc. (d/b/a Talawar Therapeutics; Delaware corporation, press-release dateline New York, NY) is a PRECLINICAL, pre-revenue biotech - the first company formed to develop assets discovered by biotech company-builder Khanda Therapeutics, L.P. Its lead program TALA-125 is a novel anti-IL-13 x anti-IL-18 bispecific antibody for atopic dermatitis that pairs two clinically validated, largely orthogonal mechanisms to break the monotherapy 'efficacy ceiling'; it has NOT yet entered the clinic - first-in-human is expected 1Q2027, interim Phase 1 data 4Q2027, and post-deal cash is meant to fund it through a Phase 2b proof-of-concept readout in 2H2028. Two further discovery-phase programs, TALA-307 and TALA-711, target additional immunology indications. Leadership: CEO Marc Schegerin, MD, MBA (ex-COO/CFO Morphic Therapeutic, ex-CFO/Head of Strategy ArQule); CMO Fabio Nunes, MD, MMSc (ex-VP Dermatology & Respiratory Clinical Development, Johnson & Johnson); board chair Dan Becker, MD, PhD (Managing Director, Access Biotechnology - the founding investor); Praveen Tipirneni, MD (ex-CEO Morphic Therapeutic and Caldera Therapeutics) joins the board. The $225M oversubscribed PIPE at $10.00 (led by Access Biotechnology, with Bain Capital Life Sciences, Deep Track Capital, RA Capital, Janus Henderson, Vianti, Farallon) is nearly 2x the $120M pre-PIPE equity valuation of the company itself and almost 4x JATT II's $60M trust - the deal is effectively a PIPE-financed IPO of a preclinical asset with zero revenue and no clinical data.
Source: 8-K, accession 0001193125-26-286926 · as of Jun 29, 2026 · extraction confidence: high
What the company says about itself
Web research — not audited'Duality by Design' - bispecific antibodies pairing independent disease drivers in one therapy for atopic dermatitis patients stuck under the efficacy ceiling of current standard of care.
- Markets:
- Atopic dermatitis and other autoimmune/inflammatory conditions
- Products:
- TALA-125 (anti-IL-13 x anti-IL-18 bispecific, lead); TALA-307 and TALA-711 (discovery-phase)
Source: https://talawartx.com · captured Aug 15, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Talawar Therapeutics is merging with JATT II Acquisition (JATT), a $60M SPAC currently marked Deal announced and trading at $12.36 against $10.07 in trust per share.
| Headline equity value | $120M |
| Effective valuation (all shares) | $422M+252% vs headline |
| Sponsor promote | 22.3% |
| PIPE | ≈ $225M · unsourcedcommon@10.00 |
| Minimum cash to close | $125M |
Structure per SEC accession(s) 0001193125-26-286926. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Was this deal done at an expensive or a cheap valuation?
SpacBrain’s read on the price
No multiple can be computed
Talawar Therapeutics (Talawar Tx Inc.) has no meaningful revenue yet, so no multiple is computable — this is priced on a story, not on financials. The deal still values it at $422.2M.
The company reports no meaningful sales yet, so there is nothing to divide the price by.
Post-dilution equity (net debt unknown).
No meaningful revenue in the most recent reported period.
Not computable — the filings show no meaningful revenue for the most recent reported period.
$1 of their sales costs $22.87 on the open market. Median of 4 listed companies we judged a true comparable, which individually run from 4.84× to 43.92×. Their share prices are from 15 August 2026, not today.
What qualifies the figures above
- Struck on the post-dilution value of $422.2M, not the announced $120M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.
- APGE, CTNM, CBIO, CGEN, EDSA, ZURA, SEPN, CLDX, TIL, IBIO, OABI, TCRT have no revenue to divide by, so they are shown but left out of the peer median.
The listed companies it is measured against
| Ticker | Company | Mkt cap | EV / revenue | EV / EBITDA | Why it’s comparable |
|---|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | $10.2B | — | — | Apogee Therapeutics' lead APG777 is a clinical-stage anti-IL-13 antibody for atopic dermatitis - the most direct listed comp for TALA-125's target pathway, indication and stage.more ▾less ▴ |
| CTNM | Contineum Therapeutics Inc | $427M | — | — | Direct comp: Biotechnology & Medical Research (NEC); small-cap ($427m); shares pipe, immunology, discovered, indications, preclinical, phase with the target's own description; forward EV/Sales 53.8x.more ▾less ▴ |
| REGN | Regeneron Pharmaceuticals, Inc. | $82.7B | 4.8x | 16.0x | Regeneron's Dupixent (IL-4Ra) is the standard-of-care whose efficacy ceiling Talawar claims to shatter - the incumbent that defines the atopic dermatitis market.more ▾less ▴ |
| CBIO | Crescent Biopharma, Inc. | $327M | — | — | Operational comp: Pharmaceuticals (NEC); small-cap ($327m); shares bispecific, antibody, monotherapy, efficacy, clinically, biotechnology with the target's own description; forward EV/Sales 251.5x.more ▾less ▴ |
| ANAB | AnaptysBio, Inc. | $1.7B | 7.3x | 40.9x | AnaptysBio is a clinical-stage antibody company focused squarely on inflammation & immunology - comparable pre-commercial I&I antibody valuation anchor.more ▾less ▴ |
| CGEN | Compugen Ltd. | $145M | — | — | Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($145m); shares preclinical, immunology, discovered, therapeutic, monotherapy, discovery with the target's own description; forward EV/Sales 9.2x.more ▾less ▴ |
| CNTB | Connect Biopharma Holdings Limi | $161M | 43.9x | — | Connect Biopharma's rademikibart (anti-IL-4Ra) targets the same atopic dermatitis/inflammatory space at clinical stage with a small-cap valuation like Talawar's.more ▾less ▴ |
| EDSA | Edesa Biotech Inc | $17M | — | — | Operational comp: Bio Therapeutic Drugs; micro-cap ($17m); shares dermatology, respiratory, biotech, dermatitis, anti, phase with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| NKTR | Nektar Therapeutics | $2.5B | 38.5x | — | Nektar's rezpegaldesleukin is in late-stage development for atopic dermatitis - another single-asset-driven I&I biologics story at comparable market value.more ▾less ▴ |
| ZURA | Zura Bio Limited | $534M | — | — | Zura Bio develops bispecific/dual-pathway antibodies (tibulizumab) for immune-mediated diseases - the same two-pathways-one-molecule thesis at preclinical-to-early-clinical stage.more ▾less ▴ |
| SEPN | Septerna, Inc. | $1.2B | — | — | Operational comp: Biotechnology & Medical Research (NEC); small-cap ($1.2bn); shares therapeutic, immunology, respiratory, inflammation, validated, biotechnology with the target's own description; forward EV/Sales 21.8x.more ▾less ▴ |
| CLDX | Celldex Therapeutics, Inc. | $1.8B | — | — | Operational comp: Biotechnology & Medical Research (NEC); small-cap ($1.8bn); shares bispecific, therapeutics, atopic, dermatitis, antibody, antibodies with the target's own description; forward EV/Sales 1630.1x.more ▾less ▴ |
| TIL | Instil Bio, Inc. | $75M | — | — | Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($75m); shares bispecific, antibodies, antibody, efficacy, anti, novel with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| IBIO | iBio Inc | $15M | — | — | Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($15m); shares bispecific, anti, antibody, biotech, antibodies, pre with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| OABI | OmniAb Inc | $267M | — | — | Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($267m); shares antibodies, bispecific, biotech, therapeutics, discovery, antibody with the target's own description; forward EV/Sales 14.9x.more ▾less ▴ |
| TCRT | Alaunos Therapeutics Inc | $7M | — | — | Operational comp: Bio Therapeutic Drugs; micro-cap ($7m); shares expected, therapeutics, pre, fund, clinical, capital with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
Which companies belong on this list is our judgement, and the sentence beside each one is the whole of our reasoning — disagree with it and the verdict above changes. Rows marked context only are shown because they are informative, but they are deliberately left out of the median. The multiples come from listed-company data priced Aug 15, 2026; a private target’s deal multiple is not audited the way theirs are.
Common questions
Is Talawar Therapeutics going public?
Talawar Therapeutics has a signed merger with the SPAC JATT II Acquisition (JATT), announced Jun 29, 2026. Deal status: Definitive (DA signed).
What is Talawar Therapeutics's SPAC deal valuation?
The announced headline equity value is $120M, but counting every share class — founder promote, PIPE and public shares — the effective valuation is $422M, 252% above the headline.
Was Talawar Therapeutics bought at an expensive or a cheap valuation?
Talawar Therapeutics (Talawar Tx Inc.) has no meaningful revenue yet, so no multiple is computable — this is priced on a story, not on financials. The deal still values it at $422.2M.
Does Talawar Therapeutics have revenue?
No meaningful reported revenue in its most recent filed period — the deal is priced on a story and projections, not on financial results. Treat every valuation multiple accordingly.
Educational content, not investment advice.
- Nanyang Biologics — with RFAI ($1.5B) · pre-revenue
- DRC Medicine — with RIBB ($350M)
- First Choice Healthcare — with WSTN ($650M)
- Veraxa Biotech — with VACH
- Minovia Therapeutics — with LPAA ($180M)
- JTTT — JATT III Acquisition Corp · Searching